Yale Podnos compensation by year
Starling Oncology Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $447,000 |
| Bonus | $137,625 |
| Stock awards | $179,080 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $12,200 |
| Total | $775,905 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Starling Oncology, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197350, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 157,088 | $559,233 | — |
| RSU | 41,523 | $147,822 | — |
| RSU | 16,610 | $59,132 | — |
| RSU | 13,148 | $46,807 | — |
| RSU | 4,241 | $15,098 | — |
| RSU | 3,541 | $12,606 | — |
| Option | 21,524 | — | $7.09 |
| Option | 17,974 | — | $1.87 |
| Option | 32,869 | — | $2.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Starling Oncology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Starling Oncology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Virnich | Chief Executive Officer | $1,934,930 |
| Yale Podnos · this page | Chief Medical Officer | $775,905 |
| Robert Carter | Chief Financial Officer | $734,130 |
The full Starling Oncology compensation record
free company briefThis page is one person within Starling Oncology's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Starling Oncology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Starling Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat